News
TXG
8.77
+1.62%
0.14
10X Genomics Faces Mixed Outlook Amid Funding Uncertainties
TipRanks · 1d ago
10x Genomics Is Maintained at Neutral by JP Morgan
Dow Jones · 1d ago
10x Genomics Price Target Cut to $9.00/Share From $12.00 by JP Morgan
Dow Jones · 1d ago
JP Morgan Maintains Neutral on 10x Genomics, Lowers Price Target to $9
Benzinga · 1d ago
10x Genomics price target lowered to $15 from $18 at Stifel
TipRanks · 1d ago
Stifel Nicolaus Reaffirms Their Buy Rating on 10x Genomics (TXG)
TipRanks · 1d ago
10x Genomics price target lowered to $11 from $15 at TD Cowen
TipRanks · 1d ago
10X GENOMICS INC <TXG.O>: STIFEL CUTS TARGET PRICE TO $15 FROM $18
Reuters · 1d ago
10X GENOMICS <TXG.O>: DEUTSCHE BANK CUTS TARGET PRICE TO $10 FROM $16
Reuters · 1d ago
10x Genomics price target lowered to $9 from $12 at JPMorgan
TipRanks · 1d ago
10X GENOMICS INC <TXG.O>: JP MORGAN CUTS TARGET PRICE TO $9 FROM $12
Reuters · 1d ago
10x Genomics (NASDAQ:TXG) adds US$65m to market cap in the past 7 days, though investors from five years ago are still down 89%
Simply Wall St · 1d ago
10x Genomics: Navigating Uncertainty Amidst Regional Variations and Budget Constraints
TipRanks · 1d ago
10x Genomics: Hold Rating Amidst Research Funding Uncertainty and Market Risks
TipRanks · 1d ago
10x Genomics (TXG) Gets a Buy from Barclays
TipRanks · 1d ago
10X GENOMICS INC <TXG.O>: JEFFERIES CUTS TARGET PRICE TO $16 FROM $19
Reuters · 1d ago
10x Genomics CEO Calls NIH The 'Foundational Jewel' Of Biomedical Progress, Says 40% To 50% Of Revenue Supported By Academic And Government Research Funding — Pulls Full Year Revenue Guidance
Benzinga · 2d ago
10x Genomics Reports Q1 2025 Financial Results
TipRanks · 2d ago
10x Genomics: Hold Rating Amid Uncertain Outlook and Strategic Cost Management
TipRanks · 2d ago
Compared to Estimates, 10x Genomics (TXG) Q1 Earnings: A Look at Key Metrics
NASDAQ · 2d ago
More
Webull provides a variety of real-time TXG stock news. You can receive the latest news about 10X Genomics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TXG
More
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.